Picture of Pharming NV logo

PHARM Pharming NV Share Price

0.000.00%
nl flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+38.23%
3m+41.75%
6m+39.64%
1yr+29.98%
Volume Change (%)
10d/3m+241.72%
Price vs... (%)
52w High-0.18%
50d MA+37.37%
200d MA+39.7%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)52.9
PEG Ratio (f)7.85
EPS Growth (f)7.22%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.65
Price to Tang. Book5.87
Price to Free Cashflow47.01
Price to Sales3.76
EV to EBITDA15.58

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital7.26%
Return on Equity14.95%
Operating Margin12.94%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m101.07159.38189.16212.17198.87206.84234.4862.49%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/a+22.88-6.61-49.81-46.41+66.67n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Pharming NV EPS forecast chart

Profile Summary

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
November 11th, 1988
Public Since
July 2nd, 1998
No. of Employees
321
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
nl flag iconEuronext - Amsterdam
Shares in Issue
652,414,282
Blurred out image of a map
Address
Darwinweg 24, LEIDEN, 2333 CR
Web
https://www.pharming.com/
Phone
+31 715247400
Auditors
Deloitte Accountants B.V.

PHARM Share Price Performance

Upcoming Events for PHARM

Q3 2022 Pharming Group NV Earnings Release

FAQ

Or unlock with your email

Or unlock with your email